• Vaccine Name: Cancer Subunit NY-ESO-1 Protein Vaccine
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0011366
• Type: Subunit vaccine
• Status: Research
• CTAG1B gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0000757
  • Description: ISCOMATRIX adjuvant (Maraskovsky et al., 2004).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: BALB/c and C57BL/6
• Vaccination Protocol: Mice were immunized s.c. with 100 μl into the scruff of the neck with the NY-ESO-1 vaccine (5 μg of both NY-ESO-1 and ISCOPREP saponin), or with NY-ESO-1 protein (5 μg of protein) or with the ISCOMATRIX adjuvant (5 μg of ISCOPREP saponin) (Maraskovsky et al., 2004).
• Immune Response: The NY-ESO-1 vaccine induced strong NY-ESO-1-specific IFN-gamma and IgG2a responses in C57BL/6 mice. Furthermore, the NY-ESO-1 vaccine induced NY-ESO-1-specific CD8(+) CTLs in HLA-A2 transgenic mice that were capable of lysing human HLA-A2(+) NY-ESO-1(+) tumor cells (Maraskovsky et al., 2004).
• Challenge Protocol: B16 melanoma cells were transfected using electroporation with the mammalian expression plasmid, pCDNA3, encoding the cDNA for NY-ESO-1 (Invitrogen, Carlsbad, CA). Selection with G418 (800 μg/ml) and limit-dilution cloning yielded a clone expressing NY-ESO-1 (B16-NY-ESO-1) as determined by IHC and quantitative real-time PCR. C57BL/6 mice were vaccinated twice (at 0 and 4 weeks) with the NY-ESO-1 vaccine, or with the ISCOMATRIX adjuvant alone as a control. Four weeks after the second immunization, mice were challenged with B16-NY-ESO-1. The tumor cells (1 × 10^4) were injected s.c. on the back, and tumor volume was measured over time (Maraskovsky et al., 2004).
• Efficacy: C57BL/6 mice, immunized with the NY-ESO-1 vaccine, were protected against challenge with a B16 melanoma cell line expressing NY-ESO-1 (Maraskovsky et al., 2004).